Monograph
A16AX05 - Zinc Acetate |
Not porphyrinogenic |
NP |
Rationale
There is no data indicating zinc acetate is interacting with CYP and it is therefore probably not porphyrinogenic.
Chemical description
Zinc salt
Therapeutic characteristics
Zinc acetate is indicated for the treatment of Wilson’s disease.
Metabolism and pharmacokinetics
Around 80% of zinc is bound to erythrocytes and the rest is mainly bound to albumin and other plasma proteins. The elimination of zinc results primarily from faecal excretion. The faecal excretion is in the greatest part due to the passage of unabsorbed zinc but it is also due to endogenous intestinal secretion.
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). zinc acetate.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024